Kailera Therapeutics shares jump 63% after $625 million obesity IPO
The obesity drug developer's debut gives the incretin pipeline a well-funded new entrant outside the Lilly-Novo duopoly.
The wire
- 01Kailera Therapeutics raised $625 million in its initial public offering, and the shares closed up 63% on their first day of trading, Bloomberg reported.
- 02A large obesity IPO signals continued investor appetite for incretin competitors, which shapes future supply and pricing options for prescribers and patients.
- 03Clinical readouts, not listing-day performance, will determine whether Kailera's candidates reach the market; the company remains pre-approval.
From the source
Read at bloomberg.comObesity Firm Kailera Therapeutics Up 63% After $625 Million IPO
